Takeda Pharmaceutical, founded in 1781 as a drug wholesaler in Osaka, Japan, has evolved into a global pharmaceutical giant through organic growth, strategic acquisitions (Millennium, Nycomed, Shire), and a strong focus on R&D in areas like oncology, rare diseases, and vaccines.
Chobei Takeda opens a drug wholesale business in Osaka, Japan, laying the foundation for Takeda Pharmaceutical. #history #pharmaceutical
Takeda starts manufacturing its own traditional herbal medicines, moving beyond wholesale into production. #pharmaceutical
The company officially adopts the name Takeda Shoten, marking its formal identity as a pharmaceutical enterprise. #history
Takeda begins exporting pharmaceuticals to China, starting its international expansion. #global #pharmaceutical
Takeda incorporates as Takeda Pharmaceutical Company Limited, transitioning from a family business to a modern corporation. #corporate
Takeda starts manufacturing synthetic pharmaceuticals, advancing from herbal remedies to modern medicine. #pharmaceutical #innovation
Takeda establishes its first research laboratory, formalizing a commitment to R&D. #research
Takeda is listed on the Tokyo Stock Exchange, raising capital for expansion. #finance #IPO
Takeda launches Alinamin, a synthetic vitamin B1 product, becoming a blockbuster drug and establishing Takeda's reputation in vitamins. #pharmaceutical #health
Takeda introduces its first antibiotic, expanding into anti-infectives. #pharmaceutical
Takeda Chemical Industries USA is founded in New York, marking its first direct presence in the United States. #global #expansion
Takeda launches its own synthetic penicillin, strengthening its antibiotic portfolio. #pharmaceutical
Takeda opens its first manufacturing plant outside Japan in the United States, boosting local production. #manufacturing #global
Takeda launches its first anticancer drug, entering the oncology market. #oncology #pharmaceutical
Takeda Europe is established to coordinate operations across the continent, expanding its European footprint. #global #expansion
Takeda launches a novel antihypertensive drug, strengthening its cardiovascular portfolio. #cardiovascular #pharmaceutical
Takeda makes its first major US acquisition, acquiring a small biotech firm to grow its pipeline. #acquisition #growth
Takeda restructures its R&D organization to improve efficiency and focus on global therapeutic areas. #R&D #restructuring
Takeda launches a new diabetes medication, becoming a player in metabolic diseases. #diabetes #pharmaceutical
Takeda acquires Millennium Pharmaceuticals for $8.8 billion, gaining access to the cancer drug Velcade and a strong oncology pipeline. #acquisition #oncology
Takeda acquires Nycomed, a Swiss-based pharmaceutical company, to expand in Europe, emerging markets, and gastroenterology. #acquisition #global
Takeda forms a joint venture in Brazil, strengthening its presence in Latin America. #global #expansion
Takeda acquires Baxter's vaccine business, adding dengue and other vaccines to its portfolio. #vaccine #acquisition
Takeda launches a new oncology drug, bolstering its cancer pipeline. #oncology #pharmaceutical
Takeda acquires Ariad Pharmaceuticals for $5.2 billion, gaining cancer drugs Iclusig and brigatinib. #acquisition #oncology
Takeda announces its intent to acquire Shire plc for $62 billion, creating one of the top 10 global pharma companies. #merger #pharmaceutical
Takeda completes the Shire acquisition, becoming a global leader in rare diseases, neuroscience, and gastroenterology. #merger #pharmaceutical
Takeda restructures to focus on rare diseases, oncology, and neuroscience, divesting non-core assets. #strategy #restructuring
To reduce debt from the Shire acquisition, Takeda sells several non-core assets, including some products and subsidiaries. #divestiture #finance
Christophe Weber steps down after leading Takeda through the Shire acquisition; succeeded by Teresa Zhang as new CEO. #leadership
Takeda advances several gene therapy candidates into late-stage trials, emphasizing innovation in rare genetic diseases. #genetherapy #R&D
Takeda sells its over-the-counter and consumer health business in Japan to focus on prescription drugs. #divestiture
Takeda's dengue vaccine TAK-003 receives approval in multiple countries, becoming a key revenue driver. #vaccine #globalhealth